Edgewise Therapeutics, Inc. (EWTX) Analyst Estimates Annual - Discounting Cash Flows
EWTX
Edgewise Therapeutics, Inc.
EWTX (NASDAQ)
Period Ending: 2030
12-31
2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
Number of Analysts 7 7 8 9 7 0 0
Estimated Revenue
Low 458.4 200.6 130.2 2.19 1.34 0 0
Average 776.3 339.7 130.2 14.91 2.27 0 0
High 1,223 535 130.2 32.78 3.58 0 0
Estimated EBITDA
Low 0 0 0 0 0 0 0
Average 0 0 0 0 0 0 0
High 0 0 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0 0 0
Average 0 0 0 0 0 0 0
High 0 0 0 0 0 0 0
Estimated Net Income
Low 63.27 -138.5 -236.3 -305.2 -254.7 -169.4 -149
Average 135.3 -79.26 -223 -256.7 -233.6 -167.8 -140.5
High 236.4 -37.07 -122.2 -160.6 -154 -161.1 -131.9
Estimated SGA Expenses
Low 0 0 0 0 0 0 0
Average 0 0 0 0 0 0 0
High 0 0 0 0 0 0 0
Estimated EPS
Low 0.615 -1.35 -2.3 -2.97 -2.47 -1.65 -1.61
Average 1.31 -0.77 -1.76 -2.36 -2.11 -1.6 -1.49
High 2.3 -0.36 -1.19 -1.56 -1.5 -1.57 -1.43
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program